文献速递乳腺癌放疗放疗物理与技术

既往乳房增大患者保乳治疗与大分割放疗的可行性

Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation.
PubMed 文献 · Pract Radiat Oncol · 2020-03-20

该回顾性研究纳入2006至2017年70例有乳房增大(BA)史的乳腺癌患者共71例次保乳治疗(BCT),其中54.9%接受大分割全乳放疗、81.7%接受瘤床加量。中位随访1.9年,25.4%出现新发或加重的包膜挛缩,12.7%转诊整形外科行修复手术,无假体丢失病例;医生评估87.4%美容效果为优或良。结论认为BA并非BCT禁忌,大分割放疗未对假体结局产生不利影响。

要点

  • BA史乳腺癌患者BCT后假体丢失风险低,本组无假体丢失病例。
  • 25.4%出现新发或加重包膜挛缩,12.7%转诊整形外科修复。
  • 大分割全乳放疗未对假体结局产生不利影响,BA非BCT禁忌。

核心结论

  • 有BA史的乳腺癌患者行BCT后假体丢失风险低,大分割放疗不 adverse 影响假体结局,BA不构成BCT禁忌。

研究设计与样本

  • 单中心回顾性研究,纳入2006年1月至2017年1月有BA史并选择BCT的乳腺癌患者,共70例患者71例次乳腺癌。

主要发现

  • 54.9%接受大分割全乳切线放疗,81.7%接受瘤床加量,平均随访1.9年。
  • 71例次中25.4%出现新发或加重包膜挛缩,12.7%转诊整形外科行修复手术,无假体丢失病例。
  • 单因素分析中假体位置、假体置入至诊断时间、放疗类型、瘤床加量、BMI和肿瘤大小均与新发或加重包膜挛缩无关。
  • 12例已有包膜挛缩患者中仅2例出现加重。
  • 医生评估BCT后美容效果为优或良者占87.4%。

临床怎么用

  • 可向有BA史的患者说明BCT后包膜挛缩风险,但多数美容结局为优或良,BA不应被视为BCT禁忌。
  • 大分割全乳放疗可作为有BA史乳腺癌患者BCT的放疗选择之一。

局限性

  • 回顾性单中心设计,样本量有限(70例患者71例次乳腺癌),平均随访1.9年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cosmetic outcomes and rate of implant loss are poorly characterized among patients with breast cancer with previous breast augmentation (BA) who undergo breast-conservation therapy (BCT). Here we determine capsular contracture and implant loss frequency after BCT among patients receiving contemporary whole-breast radiation therapy (RT). METHODS AND MATERIALS: Patients with breast cancer with a history of BA presenting to our institution from January 2006 to January 2017 who elected for BCT were included. Seventy-one breast cancers in 70 patients with a history of BA electing for BCT were retrospectively identified. Clinicopathologic, treatment, and outcome variables were examined. Whole-breast RT included conventional and hypofractionated schedules with and without a boost. Rates of implant loss and cosmetic outcomes among patients who did and did not develop a new/worse contracture based on physician assessment were compared. RESULTS: In the study, 54.9% of patients received radiation using hypofractionated whole-breast tangents; 81.7% received a boost. In addition, 18 out of 71 cases (25.4%) developed a new/worse contracture after BCT with a mean follow-up of 1.9 years. Furthermore, 9 out of 71 cases (12.7%) were referred to a plastic surgeon for revisional surgery. There were no implant-loss cases. On univariate analysis, implant location, time from implant placement to diagnosis, RT type, RT boost, body mass index, and tumor size were not associated with new/worse contracture. Of 12 patients with existing contracture, only 2 developed worsening contracture. Physician assessment of cosmetic outcome after BCT was noted to be excellent or good for 87.4% of patients. CONCLUSIONS: BCT for breast cancer patients with prior history of BA has a low risk of implant loss. Hypofractionated RT does not adversely affect implant outcomes. Patients should be counseled regarding risk for capsular contracture, but the majority have good/excellent outcome; BA does not represent a contraindication to BCT.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Tadros AB, Moo TA, Zabor EC, et al. Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation. Pract Radiat Oncol. 2020. PMID: 32006728. doi:10.1016/j.prro.2020.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。